Pradeep .V. Mahajan

Home / Pradeep .V. Mahajan

Dr. Mahajan completed his masters in General Surgery from Marathwada University, Maharashtra, and went on to pursue a Diploma in Urology at the University of Vienna, Austria. In a career-changing move, after three decades of being a successful general and uro-surgeon, he started his brainchild-StemRx Bioscience Solutions Pvt. Ltd. in the year 2011. This was to focus on in-depth research in the field of Regenerative Medicine and Cell-Based Therapy which he believes is the solution to address the limitations of conventional therapeutic modalities. To this effect, he underwent and continues to undergo intensive training in the United States. He has devised personalized treatment protocols in cell-based therapy for more than 75 health conditions.
Dr. Mahajan is a Life Member and Joint Secretary of The Stem Cell Society of India as well as Vice President of Anti-Aging Foundation, Delhi and Scientific National Advisor, Indian Stem Cell Study Group. He has been appointed as Hon. Associate Professor of Regenerative Medicine and Cell-Based Therapy at Dr. R N Cooper Hospital, Mumbai, and Faculty for MD Transfusion Medicine at KEM Hospital, Mumbai. Examiner for various fellowship courses with D.Y. Patil Institute, Kolhapur.
Dr. Mahajan’s academic collaborations include being a Member of the board of studies in Amity University, ITM University, Raipur / MUHS, for Ph.D. courses, M.Sc., and Fellowship Programs in stem cells and regenerative medicine. Among his international associations, a clinical trial in collaboration with the Ohio State University, the USA on Cell-Based Therapy for Avascular Necrosis is noteworthy, wherein Dr. Mahajan is a Principal Investigator. He is also a principal investigator in collaboration with Indiana University, Indianapolis under the guidance of Dr. Chandan Sen to conduct the first human clinical trials using TNT technology as well as treatment of leukoderma using TNT technology in India. Dr. Mahajan has also collaborated with AIIMS – India’s premier healthcare institute to launch various projects using Exosomes. His recent international ventures include an extension of StemRx facilities in Africa and collaboration with an organization in Japan to launch NK cell (cancer immunotherapy) technology for solid tumors in India. His company StemRx is also working on CAR-T cell technology in India. He has published an international patent for treatment of Avascular Necrosis using the Regenerative Medicine approach and Indian patents for Avascular Necrosis, Ankylosing Spondylitis, Ischemic-tolerance Mesenchymal Stem Cell treatment/technology and isolation of dental pulp stem cells and Autism as well. He has 13 papers publications to his credit. Dr. Mahajan has also been appointed by Government of India and Government of Maharashtra as consultant and panel doctor with the director-general of the shipping and labor department.